Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in CholangiocarcinomaMutant-IDH1 Promotes Immunoevasion in Cholangiocarcinoma
Wu M, Shi L, Dubrot J, Merritt J, Vijay V, Wei T, Kessler E, Olander K, Adil R, Pankaj A, Tummala K, Weeresekara V, Zhen Y, Wu Q, Luo M, Shen W, García-Beccaria M, Fernández-Vaquero M, Hudson C, Ronseaux S, Sun Y, Saad-Berreta R, Jenkins R, Wang T, Heikenwälder M, Ferrone C, Goyal L, Nicolay B, Deshpande V, Kohli R, Zheng H, Manguso R, Bardeesy N. Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in CholangiocarcinomaMutant-IDH1 Promotes Immunoevasion in Cholangiocarcinoma. Cancer Discovery 2022, 12: 812-835. PMID: 34848557, PMCID: PMC8904298, DOI: 10.1158/2159-8290.cd-21-1077.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Duct NeoplasmsBile Ducts, IntrahepaticCholangiocarcinomaCTLA-4 AntigenDioxygenasesDNA-Binding ProteinsHumansInterferon-gammaIsocitrate DehydrogenaseMiceMutationConceptsTumor maintenanceKetoglutarate-dependent enzymesDiscovery of mechanismsDNA demethylaseResponse genesCell-specific ablationCTLA4 blockadeMouse modelEnzyme inhibitsImmune checkpoint activationCytotoxic T-cell functionTumor cellsSuppression of CD8T-cell depletionIssue featureT cell activityT cell recruitmentT cell functionNew therapeutic strategiesInterferon γ expressionIsocitrate dehydrogenase 1 (IDH1) mutationTET2Receptor 1Γ expressionInhibitor efficacy